Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
27/02/202015:05Business WireAcceleron Reports Fourth Quarter and Full Year 2019 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
26/02/202006:00Business WireAcceleron to Participate in Two Upcoming Healthcare Investor ConferencesNASDAQ:XLRNAcceleron Pharma Inc
18/02/202006:00Business WireAcceleron to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on February 27, 2020NASDAQ:XLRNAcceleron Pharma Inc
14/02/202016:59Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
14/02/202012:39Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XLRNAcceleron Pharma Inc
10/02/202017:02Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:XLRNAcceleron Pharma Inc
27/01/202015:15Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
27/01/202015:01Business WireAcceleron Announces Sotatercept Achieved Primary & Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Pati...NASDAQ:XLRNAcceleron Pharma Inc
23/01/202015:15Business WireAcceleron Announces Change to Executive Management TeamNASDAQ:XLRNAcceleron Pharma Inc
09/01/202005:59Business WireNew England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST TrialNASDAQ:XLRNAcceleron Pharma Inc
06/01/202006:00Business WireAcceleron to Participate in the 38th Annual J.P. Morgan Healthcare ConferenceNASDAQ:XLRNAcceleron Pharma Inc
30/12/201906:30Business WireAcceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration AgreementNASDAQ:XLRNAcceleron Pharma Inc
17/12/201917:20Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:XLRNAcceleron Pharma Inc
09/12/201915:30Business WireReblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of...NASDAQ:XLRNAcceleron Pharma Inc
09/12/201906:30Business WireAcceleron Appoints Jay T. Backstrom, M.D., M.P.H., to Newly Created Role as Head of Research and DevelopmentNASDAQ:XLRNAcceleron Pharma Inc
06/12/201911:45Dow Jones NewsBristol-Myers, Acceleron: FDA Drops Planned Panel Review of ReblozylNASDAQ:XLRNAcceleron Pharma Inc
06/12/201911:05Business WireBristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)NASDAQ:XLRNAcceleron Pharma Inc
06/12/201907:00Business WireAcceleron Appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of DirectorsNASDAQ:XLRNAcceleron Pharma Inc
04/12/201915:01Business WireAcceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” RankingsNASDAQ:XLRNAcceleron Pharma Inc
03/12/201907:35Dow Jones NewsBristol-Myers, Acceleron: FDA Panel to Review Reblozyl in Myelodysplastic SyndromesNASDAQ:XLRNAcceleron Pharma Inc
03/12/201906:38Business WireBristol-Myers Squibb & Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in...NASDAQ:XLRNAcceleron Pharma Inc
02/12/201906:00Business WireAcceleron to Host Conference Call and Webcast to Review Data Presented at the 61st American Society of Hematology Annual Meet...NASDAQ:XLRNAcceleron Pharma Inc
08/11/201912:30Dow Jones NewsAcceleron Pharma Shares Gain Ground After FDA Approves ReblozylNASDAQ:XLRNAcceleron Pharma Inc
08/11/201912:20Dow Jones NewsFDA Approves Celgene's and Acceleron's Reblozyl to Treat Rare Blood DisorderNASDAQ:XLRNAcceleron Pharma Inc
08/11/201911:33Business WireFDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular R...NASDAQ:XLRNAcceleron Pharma Inc
06/11/201908:05Business WireAcceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual MeetingNASDAQ:XLRNAcceleron Pharma Inc
06/11/201906:59Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
06/11/201906:53Business WireAcceleron Reports Third Quarter 2019 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
29/10/201906:00Business WireAcceleron to Webcast Third Quarter 2019 Operating and Financial Results on November 6, 2019NASDAQ:XLRNAcceleron Pharma Inc
16/09/201915:30Business WireAcceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular DystrophyNASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN

Su Consulta Reciente

Delayed Upgrade Clock